Pain Studies In The News

Stress and neck pain more common in women than men
December 6, 2010 Source: University of Gothenburg
Neck pain is more common in women than men, irrespective of occupation or age, reveals a new thesis. Stressed young women develop more neck pain than their male counterparts. Women also perceive everyday life to be more stressful.
[More]

St. Jude Medical neurostimulation study demonstrates sustained improvement in chronic low back pain symptoms and quality of life
December 3, 2010 Source: St. Jude Medical, Inc.
St. Jude Medical, Inc. today announced two-year results in a post-market clinical study evaluating neurostimulation (spinal cord stimulation) for the management of chronic low back pain. The study found that 70 percent of neurostimulation patients reported overall pain relief of 50 percent or better at their final two-year visit. Additionally, 88 percent of these patients reported that their quality of life was improved or greatly improved.
[More]

Intervention reduces chronic pain visits: consultation of 15-30 minutes redirects patients
December 1, 2010 Source: Emergency Department Management
Behavioral Health Central. December 1, 2010
A simple behavioral health consultation of 15-30 minutes has helped reduce the number of chronic pain patients who use the ED at Providence Newberg Medical Center in Newberg, OR, as their primary source of medical care. For the intervention, grad students would meet patients and introduce the "bio-psychosocial model," which, is a way of validating the patient's physical pain while introducing the concept that there are other treatment options besides opioids.
[More]

19 More Pain Studies In The News

 Product News/Clinical Trial Results

Propoxyphene: withdrawal - risk of cardiac toxicity
November 19, 2010 Source: U.S. Food and Drug Administration
FDA notified healthcare professionals that Xanodyne Pharmaceuticals has agreed to withdraw propoxyphene (Sold as Darvon, Darvocet, and generics), an opioid pain reliever used to treat mild to moderate pain, from the U.S. market at the request of the FDA, due to new data showing that the drug can cause serious toxicity to the heart, even when used at therapeutic doses.
[More]

Horizon Pharma presents HZT-501 long-term safety data and LODOTRA Phase 3 data at the American College of Rheumatology annual meeting
November 9, 2010 Source: Horizon Pharma
Horizon Pharma, Inc. today announced results from a long-term safety study of HZT-501, a novel single-tablet formulation of ibuprofen (800 mg) and high-dose famotidine (26.6 mg). The results showed that long-term safety of HZT-501 was comparable to ibuprofen alone. In addition, safety and efficacy data from two Phase 3 trials of LODOTRA, a proprietary programmed-release formulation of low-dose prednisone, were also presented.
[More]

 Advocacy

Purdue Pharma L.P. re-launches Partners Against Pain website
December 6, 2010 Source: Purdue Pharma L.P.
Purdue Pharma L.P. unveiled an enhanced version of its popular educational website www.PartnersAgainstPain.com, making it is easier for healthcare professionals, people with pain and their caregivers to access valuable pain management information, resources and tools. In addition to information on medical conditions that cause pain, the enhanced site features customized sections for patients, caregivers and healthcare professionals.
[More]

Covidien collaborates with Arthritis Foundation on patient-education initiatives
November 22, 2010 Source: Covidien
The Arthritis Foundation and Covidien have joined forces to help advance awareness and support for millions of people suffering from osteoarthritis in the United States. The Let's Move Together Movement Tracker is an educational and physical activity resource for those suffering from arthritis. It provides patients with personalized, step-by-step support to reach their exercise goals and stay physically active--an important component of effective arthritis treatment.
[More]